How do you design randomised trials for smaller populations? A framework

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Parmar, Mahesh K B ^a   Sydes, Matthew R ^a   Morris, Tim P ^a,b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Randomised trials; Smaller populations; Trial design; Uncommon diseases

Indexed keywords

HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84997080060     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0722-3     Document Type: Letter

References (24)

1. Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014; 349:6802. doi: 10.1136/bmj.g6802.
2. Rustin GJS, van der Burg MEL, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al.Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376(9747):1155-63. doi: 10.1016/s0140-6736(10)61268-8.
3. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, et al.Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer. 2015; 51(3):271-81. doi: 10.1016/j.ejca.2014.10.027.
4. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al.Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976; 34(6):585-612.
5. Cook J, Hislop J, Adewuyi T, Harrild K, Altman D, Ramsay C, et al.Assessing methods to specify the target difference for a randomised controlled trial: DELTA (difference ELicitation in TriAls) review. Health Technol Assess. 2014; 18(28):1-166. doi: 10.3310/hta18280.
6. Cook JA, Hislop J, Altman DG, Fayers P, Briggs AH, Ramsay CR, et al.Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. Trials. 2015; 16(1):12. doi: 10.1186/s13063-014-0526-8.
7. Ioannidis JPA. Why most published research findings are false. PLOS Med. 2005; 2(8):124. doi: 10.1371/journal.pmed.0020124.
8. Djulbegovic B, Kumar A, Glasziou P, Miladinovic B, Chalmers I. Medical research: trial unpredictability yields predictable therapy gains. Nature. 2013; 500(7463):395-6. doi: 10.1038/500395a.
9. Bayar MA, Le Teuff G, Michiels S, Sargent D, Le Deley MC. New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. Stat Med. 2016; 35(19):3245-58. doi: 10.1002/sim.6942.
10. Senn S. Statistical issues in drug development. Chichester: Wiley; 2007.
11. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med. 2003; 22(14):2239-56. doi: 10.1002/sim.1430.
12. Kahan BC, Morris TP. Assessing potential sources of clustering in individually randomised trials. BMC Med Res Methodol. 2013; 13(1):58. doi: 10.1186/1471-2288-13-58.
13. Colantuoni E, Rosenblum M. Leveraging prognostic baseline variables to gain precision in randomized trials. Stat Med. 2015; 34(18):2602-17. doi: 10.1002/sim.6507.
14. Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014; 15(1):139. doi: 10.1186/1745-6215-15-139.
15. Rosenberger WF, Sverdlov O. Handling covariates in the design of clinical trials. Stat Sci. 2008; 23(3):404-19.
16. Williamson EJ, Forbes A, White IR. Variance reduction in randomised trials by inverse probability weighting using the propensity score. Stat Med. 2014; 33(5):721-37. doi: 10.1002/sim.5991.
17. Jones B, Kenward MG. Design and analysis of cross-over trials. In: Monographs on statistics & applied probability. 2nd (edn). Florida: Chapman & Hall/CRC: 2003.
18. Kahan BC, Forbes AB, Doré CJ, Morris TP. A re-randomisation design for clinical trials. BMC Med Res Methodol. 2015; 15(1):96. doi: 10.1186/s12874-015-0082-2.
19. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc Ser A (Stat Soc). 1994; 157(3):357-416. doi: 10.2307/2983527.
20. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015; 26(2):407-14. doi: 10.1093/annonc/mdu526.
21. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al.Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the Euramos-1 good response randomized controlled trial. J Clin Oncol. 2015; 33(20):2279-87. doi: 10.1200/jco.2014.60.0734.
22. Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med. 2014; 33(24):4186-201. doi: 10.1002/sim.6225.
23. Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016; 17(2):70-80. doi: 10.1016/s1470-2045(15)00396-4.
24. Tudur Smith C, Williamson PR, Beresford MW. Methodology of clinical trials for rare diseases. Best Pract Res Clin Rheumatol. 2014; 28(2):247-62. doi: 10.1016/j.berh.2014.03.004.